Revance Therapeutics, Inc. (NASDAQ:RVNC) has received an average rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $34.75.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday. Cantor Fitzgerald assumed coverage on shares of Revance Therapeutics in a research report on Thursday, July 20th. They issued an “overweight” rating and a $50.00 price objective on the stock. Aegis reissued a “buy” rating and issued a $36.00 price objective (up from $28.00) on shares of Revance Therapeutics in a research report on Friday, May 19th. ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, Piper Jaffray Companies set a $28.00 target price on shares of Revance Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th.

TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/10/revance-therapeutics-inc-rvnc-receives-43-00-consensus-target-price-from-analysts-updated-updated.html.

Revance Therapeutics (NASDAQ:RVNC) opened at 22.75 on Thursday. Revance Therapeutics has a one year low of $12.35 and a one year high of $28.30. The stock’s market cap is $688.71 million. The company’s 50-day moving average price is $24.56 and its 200-day moving average price is $21.88.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. During the same quarter last year, the firm earned ($0.88) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. Analysts forecast that Revance Therapeutics will post ($3.80) EPS for the current fiscal year.

In related news, CFO Lauren P. Silvernail sold 1,793 shares of Revance Therapeutics stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $20.20, for a total transaction of $36,218.60. Following the transaction, the chief financial officer now directly owns 36,566 shares of the company’s stock, valued at $738,633.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO L Daniel Browne sold 12,287 shares of Revance Therapeutics stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $20.20, for a total transaction of $248,197.40. Following the transaction, the chief executive officer now directly owns 183,932 shares in the company, valued at $3,715,426.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,793 shares of company stock worth $685,576. 18.86% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its stake in shares of Revance Therapeutics by 8.1% in the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 438 shares during the period. Bank of America Corp DE increased its stake in shares of Revance Therapeutics by 29.5% in the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,651 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Revance Therapeutics during the fourth quarter valued at $174,000. Trexquant Investment LP purchased a new stake in shares of Revance Therapeutics during the second quarter valued at $231,000. Finally, American International Group Inc. increased its stake in shares of Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 834 shares during the period. Institutional investors own 87.29% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.